Neogene Therapeutics IPO

Neogene Therapeutics develops personalized engineered T cell therapies for a broad spectrum of cancers.

Register for Details

For more details on financing and valuation for Neogene Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Neogene Therapeutics

Forge green plus iconForge green minus icon

What is Neogene Therapeutics's funding to date?

Neogene Therapeutics has raised $125MM to date.
Forge green plus iconForge green minus icon

When was Neogene Therapeutics founded?

Neogene Therapeutics was founded in 2018.

Neogene Therapeutics Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
9/14/2020 Series A $110MM raised $XXX.XX $XXX.XX
5/23/2019 Series Seed $15MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.